Replies to post #118984 on Biotech Values

[DewDiligence]

I think they would take whatever they could get for M118. It's not exactly a seller's market for these kinds of programs. The tepid sales of Angiomax—including almost non-existent uptake outside the US (#msg-62477060)—is probably not helping MNTA’s cause.